Long-term results of basiliximab induction immunosuppression in pediatric liver transplant recipients

Pediatric Transplantation

Volumn 9, Issue 6, 2005, Pages 741-745

  Ganschow, Rainer ^a   Grabhorn, Enke ^a   Schulz, Andrea ^a   Von Hugo, Alexander ^a   Rogiers, Xavier ^a   Burdelski, Martin ^a  

^a UNIVERSITY OF HAMBURG   (Germany)

Author keywords

Basiliximab; Children; Liver transplantation; Long term results

Indexed keywords

BASILIXIMAB; CYCLOSPORIN A; INTERLEUKIN 2 RECEPTOR ANTIBODY; METHYLPREDNISOLONE; PREDNISOLONE;

ACUTE GRAFT REJECTION; ARTICLE; CHRONIC GRAFT REJECTION; CONTROLLED STUDY; GRAFT SURVIVAL; HUMAN; HUMAN TISSUE; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INFECTION; LIVER GRAFT REJECTION; LIVER TOXICITY; LIVER TRANSPLANTATION; LONG TERM CARE; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; NEPHROTOXICITY; NEUROTOXICITY; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; REOPERATION; SEIZURE; SIDE EFFECT; SURVIVAL; TREATMENT OUTCOME; TREMOR;

ANTIBODIES, MONOCLONAL; CHILD; CHILD, PRESCHOOL; FOLLOW-UP STUDIES; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; INFANT; INFECTION; LIVER TRANSPLANTATION; LYMPHOPROLIFERATIVE DISORDERS; POSTOPERATIVE COMPLICATIONS; POSTOPERATIVE PERIOD; RECOMBINANT FUSION PROTEINS; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 27944455746     PISSN: 13973142     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1399-3046.2005.00371.x     Document Type: Article

References (22)

1. LAWEN JG, DAVIES EA, MOURAD G, et al. Randomized double-blind study of immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with mycophenolate mofetil-containing triple therapy in renal transplantation. Transplantation 2003: 75: 37-43.
2. KAHAN BD, RAJAGOPALAN PR, HALL M. Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody. Transplantation 1999: 67: 276-284.
3. HEFFRON TG, PILLEN T, SMALLWOOD GA, et al. Single-dose induction with daclizumab immediately after liver transplantation in pediatric patients. Transpl Proc 2001: 33: 1449-1451.
4. HATAKEYAMA M, TSUDO M, MINAMOTO S, et al. Interleukin-2 receptor beta chain gene: generation of three receptor forms by cloned human alpha and beta chain cDNAs. Science 1989: 244: 551-556.
5. GANSCHOW R, BROERING DC, STUERENBURG I, et al. First experience with basiliximab in pediatric liver graft recipients. Pediatr Transplantation 2001: 5: 353-358.
6. VESTER U, KRANZ B, TESTA G, et al. Efficacy and tolerability of interleukin-2 receptor blockade with basiliximab in pediatric renal transplant recipients. Pediatr Transplantation 2001: 5: 297-301.
7. DEMETRIS AJ, BATTS KP, DHILLON AP, et al. Banff schema for grading liver allograft rejection: an international consensus document. Hepatology 1997: 25: 658-663.
8. Split Research Group. Studies of pediatric liver transplantation (SPLIT): year 2000 outcomes. Transplantation 2001: 72: 463-470.
9. GANSCHOW R, NOLKEMPER D, HELMKE K, et al. Intensive care management after pediatric liver transplantation: A single center experience. Pediatr Transplantation 2000: 4: 273-279.
10. GARCIA S, ROQUE J, RUZA F, et al. Infection and associated risk factors in the immediate postoperative period of pediatric liver transplantation: a study of 176 transplants. Clin Transplant 1998: 12: 190-195.
11. NASHAN B, SSCHLITT HJ, SCHWINZER R, et al. Immunoprophylaxis with a monoclonal anti-IL-2 receptor antibody in liver transplant patients. Transplantation 1996: 61: 546-550.
12. LANGREHR JM, GLANEMANN M, GUCKELBERGER O, et al. A randomized, placebo-controlled trial with anti-interleukin-2 receptor antibody for immunosuppressive induction therapy after liver transplantation. Clin Transplantation 1998: 2: 303-312.
13. SALAMA AD, SAYEGH MH. Alternative T-cell costimulatory pathways in transplant rejection and tolerance induction: hierachy or redundancy? Am J Transplantation 2003: 3: 509-511.
14. NEUBERT RT, DELGADO I, WEBB JR, et al. Assessing lymphocyte functions in neonates for revealing abnormal prenatal development of the immune system. Teratog Carcinog Mutagen 2000: 20: 171-193.
15. DELEPESSE G, YANG LP, OHSHIMA Y, et al. Maturation of human neonatal CD4+ and CD8+ T lymphocytes into Th1/ Th2 effectors. Vaccine 1998: 16: 1415-1419.
16. PRAGHAKARAN K, WISE B, CHEN A, et al. Rational management of posttransplant lymphoproliferative disorder in pediatric recipients. J Pediatr Surg 1999: 34: 112-116.
17. SHAPIRO R, NALESNIK MA, MCCAULEY J, et al. Posttransplant lymphoproliferative disorders in adult and pediatric renal transplant patients receiving tacrolimus-based immunosuppression. Transplantation 1999: 68: 1851-1854.
18. SMETS F, LATINNE D, BAZIN H, et al. Ratio between Epstein-Barr viral load and anti-Epstein-Barr virus specific T-cell response as a predictive marker of posttransplant lymphoproliferative disease. Transplantation 2002: 73: 1603-1610.
19. MOLMENTI EP, NAGATA DE, RODEN JS, et al. Post-transplant lymphoproliferative syndrome in the pediatric liver transplant population. Am J Transplantation 2001: 1: 356-359.
20. NEWELL KA, ALONSO EM, WHITTINGTON PF, et al. Post-transplant lymphoproliferative disease in pediatric liver transplantation. Transplantation 1996: 62: 370-375.
21. YOUNES BS, MCDIARMID SV, MARTIN MG, et al. The effect of immunsuppression on posttransplant lymphoproliferative disease in pediatric liver transplant recipients. Transplantation 2000: 70: 94-99.
22. GANSCHOW R, SCHULZ T, MEYER T, BROERING DC, BURDELSKI M. Low-dose immunosuppression reduces the incidence of post-transplant lymphoproliferative disease in pediatric liver graft recipients. J Pediatr Gastroenterol Nutr 2004: 38: 198-203.